AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings

Rhea-AI Filing Summary

AC Immune SA director Roy Ervin Twyman reported his initial holdings on a Form 3. He directly holds 75,988 common shares, including 49,988 common shares underlying outstanding restricted share units. He also holds multiple share options over common shares with exercise prices between $1.84 and $7.23, expiring from 2029 through 2035.

According to the footnotes, at least one share option grant is fully vested and another will fully vest on June 17, 2026, highlighting a mix of already exercisable and time-based equity awards.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Twyman Roy Ervin

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE 1015

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	75,988(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	06/27/2029	Common Shares	36,932	$5.39	D
Share Option (right to buy)	(2)	06/25/2030	Common Shares	15,714	$6.95	D
Share Option (right to buy)	(2)	06/24/2031	Common Shares	12,865	$7.23	D
Share Option (right to buy)	(2)	06/23/2032	Common Shares	23,204	$3.15	D
Share Option (right to buy)	(2)	06/23/2033	Common Shares	37,168	$2.15	D
Share Option (right to buy)	(2)	06/30/2034	Common Shares	14,094	$4.23	D
Share Option (right to buy)	(3)	06/17/2035	Common Shares	43,299	$1.84	D

Explanation of Responses:

1. Includes 49,988 common shares underlying outstanding restricted share units.

2. The share option is fully vested.

3. The share option will fully vest on June 17, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthias Maurer, attorney-in-fact for Roy Twyman	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing for AC Immune (ACIU) disclose about Roy Ervin Twyman?

The Form 3 shows that director Roy Ervin Twyman reported his initial ownership in AC Immune. It details his direct holdings of common shares and several share option awards with different exercise prices and expiration dates, establishing his baseline equity position as an insider.

How many AC Immune (ACIU) common shares does Roy Ervin Twyman hold?

Roy Ervin Twyman directly holds 75,988 AC Immune common shares. This total includes 49,988 common shares underlying outstanding restricted share units, meaning a substantial portion of his ownership is tied to equity awards that vest over time according to the company’s terms.

What equity awards are reported for Roy Ervin Twyman in the AC Immune (ACIU) Form 3?

The filing lists several share options to buy AC Immune common shares with exercise prices ranging from $1.84 to $7.23. These options have expiration dates between 2029 and 2035, indicating long-dated incentives aligned with the company’s longer-term performance horizon.

Are Roy Ervin Twyman’s AC Immune (ACIU) share options already vested?

The footnotes state that one share option grant is fully vested, while another will fully vest on June 17, 2026. This mix of vested and unvested options shows both currently exercisable rights and future vesting tied to ongoing service or performance conditions.

Does the AC Immune (ACIU) Form 3 show any recent insider buying or selling by Roy Ervin Twyman?

No buying or selling activity is indicated; the entries are labeled as holdings. The Form 3 functions as an initial ownership statement, summarizing Twyman’s existing common share and option positions rather than reporting new market transactions or changes in his stake.